CERE
Goldman Sachs’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-1,020,921
| Closed | -$41.7M | – | 5078 |
|
|
2024
Q2 | $41.7M | Buy |
1,020,921
+3,945
| +0.4% | +$161K | 0.01% | 1093 |
|
|
2024
Q1 | $43M | Buy |
1,016,976
+484,219
| +91% | +$20.5M | 0.01% | 1073 |
|
|
2023
Q4 | $22.6M | Buy |
532,757
+208,258
| +64% | +$8.83M | ﹤0.01% | 1469 |
|
|
2023
Q3 | $7.08M | Sell |
324,499
-39,205
| -11% | -$856K | ﹤0.01% | 2223 |
|
|
2023
Q2 | $11.6M | Sell |
363,704
-13,353
| -4% | -$424K | ﹤0.01% | 1930 |
|
|
2023
Q1 | $9.2M | Buy |
377,057
+70,107
| +23% | +$1.71M | ﹤0.01% | 2078 |
|
|
2022
Q4 | $9.68M | Buy |
306,950
+61,153
| +25% | +$1.93M | ﹤0.01% | 2156 |
|
|
2022
Q3 | $6.95M | Buy |
245,797
+144,693
| +143% | +$4.09M | ﹤0.01% | 2407 |
|
|
2022
Q2 | $2.67M | Buy |
101,104
+18,839
| +23% | +$498K | ﹤0.01% | 3209 |
|
|
2022
Q1 | $2.88M | Sell |
82,265
-339,423
| -80% | -$11.9M | ﹤0.01% | 3282 |
|
|
2021
Q4 | $13.7M | Sell |
421,688
-88,059
| -17% | -$2.85M | ﹤0.01% | 2037 |
|
|
2021
Q3 | $15M | Buy |
+509,747
| New | +$15M | ﹤0.01% | 1956 |
|
|
2021
Q2 | – | Sell |
-190,266
| Closed | -$2.61M | – | 5597 |
|
|
2021
Q1 | $2.61M | Buy |
190,266
+161,957
| +572% | +$2.22M | ﹤0.01% | 3158 |
|
|
2020
Q4 | $469K | Buy |
+28,309
| New | +$469K | ﹤0.01% | 3855 |
|